The transforming growth factor-β (TGFβ) family plays an important role in many developmental 3 processes and when mutated often contributes to various diseases. Marfan syndrome is a 4 genetic disease with an occurrence of approximately 1 in 5,000. The disease is caused by 5 mutations in fibrillin, which lead to an increase in TGFβ ligand activity, resulting in abnormalities 6 of connective tissues which can be life-threatening. Mutations in other components of TGFβ 7 signaling (receptors, Smads, Schnurri) lead to similar diseases with attenuated phenotypes 8 relative to Marfan syndrome. In particular, mutations in TGFβ receptors, most of which are 9 clustered at the C-terminal end, result in Marfan-like (MFS-like) syndromes. Even though it was 10 assumed that many of these receptor mutations would reduce or eliminate signaling, in many 11 cases signaling is active. From our trafficking work in C. elegans, we noticed that many of these 12 receptor mutations that lead to Marfan-like syndromes overlap with mutations that cause mis-13 trafficking of the receptor, suggesting a link between Marfan-like syndromes and TGFβ receptor 14 trafficking. To test this hypothesis, we introduced some of these key MFS and MFS-like 15 mutations into the C. elegans TGFβ receptor and asked if receptor trafficking is altered. We find 16 that some of the mutated receptors localize to the apical surface rather than basolateral surface 17 of the polarized intestinal cells. Further, we find that these mutations result in longer animals, a 18 phenotype due to over-stimulation of the pathway and, importantly, indicating that function of the 19 receptor is not abrogated in these mutants. Our nematode models of Marfan syndrome suggest 20 that MFS and MFS-like mutations in the type II receptor lead to mis-trafficking of the receptor 21 and possibly provides an explanation for the disease, a phenomenon which might also occur in 22 some cancers that possess the same mutations within the type II receptor (e.g. colon cancer). 23 24 25 26
Introduction

47
Based on our observation that trafficking motifs in the type I and type II receptors overlap with 124 MFS, MFS-like and some cancer mutations, we hypothesized that some of these phenotypes 125 could be due to mis-trafficking of the TGFβ receptors. Therefore, we sought to test this 126 hypothesis using the model organism C. elegans where trafficking studies on TGFβ are well-127 established.
128 140 cancer cell lines or tumor specimens (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . As in the case of the MFS-like mutations, many of 141 the cancer-associated mutations in the TGFΒR2 gene cluster in the same C-terminal domain 142 (37-39) (Fig. 1) . These mutations occur in the TGFΒR2 gene (> 40 mutations) but also in the 143 TGFΒR1 gene (4 mutations) (Fig. 1) . The MFS-like R528H mutation is also present in type II 144 receptors in colon carcinoma cell lines (27) . Likewise, the mutation R537P is mutated in both 145 MFS-like patients and some cancers (3, 40) . The overlap between the mutations present in 146 MFS-like and TGFβ cancers suggests that some of these cancers might also be caused by mis-147 trafficking of the receptors.
149
Further mutational analysis of TGFβ receptors shows this C-terminus to be important for 150 signaling. Our genetic screens of the Drosophila BMP pathways identified eight missense 151 mutations in the type II receptor Punt (highlighted in yellow and green in Fig. 1, unpublished   152 data) at positions that were either identical or adjacent to residues mutated in MFS-like 153 syndromes and/or some cancers. Additionally, a human mutation associated with brachydactyly resides in the BMP type I receptor (related to the TGFβ family of receptors) in this same C-155 terminal domain (41), highlighting that both TGFβ and BMP receptors are susceptible to 156 mutation in this conserved domain (Fig. 1) . The mutations described above reside primarily in a 157 motif that overlaps with the LTA motif (residues 529-538 underlined) that disrupted the normal 158 trafficking of the receptors (Fig. 1 ).
160
We sought clues to how this C-terminal domain might be involved in trafficking by examining its 161 3D structure. Using the available structure of the type II TGFβ receptor (PDBID: 5e8V), we 162 observe that the LTA motif of the kinase domain is exposed to the exterior where interactions 163 with other proteins, particularly trafficking regulators might be expected to occur ( Fig 1B) .To 164 investigate how the MFS-like mutations might interfere with the structure and function of the 165 type II TGFβ receptor, we modeled them in Pymol (42) to better understand the relationship 166 between various residues in the LTA motif and the larger structure of the protein. In the native 167 state of the wild-type type II TGFβ receptor, residue W521 contributes to a hydrophobic core 168 that stabilizes the pairing of helices 8 and 12. This hydrophobic core is composed of residues 169 W521, L452, P498, W455, I500 and L512. The mutation W521A can cause a destabilization of 170 the pairing between helices 8 and 12, with a rearrangement of the other side-chains in the core 171 to compensate for the loss of the hydrophobic moiety of the tryptophan. R528 and R537, in 172 helices 13 and 14, respectively, are involved in long range electrostatic interactions with 173 oppositely charged residues. R528 forms a salt bridge with E428 in helix 7, and R537 forms a 174 salt bridge with E519 in helix 12. These interactions contribute to stability of the helical bundle in 175 the C-terminal domain of the type II TGFβ receptor. The mutation R528H may affect the pairing 176 of helix 13 with helix 7, but due to the limited extent of helix 13 (4 residues), the mutation may 177 have little importance for the stability of the secondary and tertiary structure of the domain or 178 interactions with partner proteins, as the two residues are relatively poorly exposed to the 179 solvent. The mutation R527P, instead, may be important both for the stability of helix 14, since 180 proline is a helix-breaker, and for the pairing of the solvent-exposed helix 14 with helix 12.
181
Moreover, R537 is on the protein surface, and may belong to a binding site for partner proteins.
183
In summary, the structural modeling suggests that the mutations found in the MFS-like patients 184 would disrupt the structure of an exposed surface domain of the type II TGFβ receptor, perhaps 185 altering its interaction with cytoplasmic trafficking and/or regulatory proteins or the function of clear; some studies have identified that mutations within the LTA motif disrupt the kinase activity 195 while others have shown that Smad phosphorylation is unaffected (1, 2). It is important to note 196 that all the mutations described above are missense mutations and should produce a full-length 197 product. Most of these residues do not alter Smad2/3 in vitro phosphorylation (23). Of note, two 198 residues that resulted in a loss of Smad phosphorylation were alanine substitutions rather than 199 naturally occurring mutations like those found in MFS-like (23), which may explain why these signaling governs body length in the worm (43) (44) (45) (46) . Loss of TGFβ signaling (e.g. mutations in 207 the type II receptor) leads to a smaller body length, and body length can be rescued (or 208 enhanced) by transgenic overexpression of signaling components specifically in the 209 hypodermis.
211
We created transgenic animals via microparticle bombardment that expressed either wild-type 
215
We expected one of three different outcomes: 1) If we observe no change in the body length of 216 the transgenic animal, the receptor may be non-functional, 2) If we observe a smaller body size,
217
it could indicate that the mutant receptor behaves in a dominant negative manner with the wild-218 type receptor, and 3) If we observe a longer body size the receptor may be active and 219 functional. Overexpression of the wild-type daf-4 led to an increase in the body length while a 220 kinase-dead version of the receptor did not change the body length (40).
222
We first showed that mutating the entire LTA motif with alanines does not disrupt receptor 223 function, as evidenced by the longer body length which requires active TGFβ signaling.
224
Importantly, we have shown that the W580R and R587H mutants result in functional receptors 225 ( Fig 2A) even though their expressed levels are lower than wild-type receptors.
227
However, the presence of the wild-type (endogenous) copy of the daf-4 gene may influence the 228 activity of the transgenic mutant receptors. Hence, we crossed each of our transgenic lines into 229 the daf-4(e1364) mutant (47), a null mutant with a small body size phenotype. Hypodermal 230 expression of wild-type copies of the transgenic daf-4 gene in this mutant fully rescues the small 231 body length of the daf-4(e1364) mutant ( Fig 2B) . Taken together, these data strongly suggest 232 that MFS-mutations do not attenuate type II TGFβ receptor activity as assayed in vivo in a 233 whole organism context. Fig 3A) . The GFP-tagged receptors allow for easy visualization of trafficking, while the 247 tdTomato acts as an internal control to detect subtle changes in the receptor expression levels 248 as well as normalization for transgene number across different strains. This construct was stably 249 integrated at a low-copy number into the worm genome using microparticle bombardment (52).
251
Confocal imaging and western blot analyses revealed that changes in the LTA motif, either 252 substituting the motif with alanines or with MFS-like mutations, resulted in significantly 253 decreased levels of receptors ( Fig 3B, C) . To rule out the possibility that the reduced levels of 254 mutant type II receptor were due to any aberrant synthesis and/or transport to the plasma 255 membrane, we examined the accumulation of DAF-4 at the plasma membrane by knocking 256 down dpy-23. dpy-23 is the μ-2 adaptin member of the AP2 complex and is required for the 257 clathrin-dependent endocytosis of various transmembrane receptors, including TGFβ (48, 53).
258
Loss of dpy-23 by RNAi leads to the suppression of clathrin-mediated endocytosis, resulting in 259 accumulation of the type I receptor SMA-6 at the plasma membrane and inhibition of BMP 260 signaling(48), and we used this particular assay as our control to determine efficacy of the RNAi 261 knockdown of dpy-23. As previously observed, knockdown of dpy-23 did not significantly impact 262 the accumulation or levels of either wild-type or mutant DAF-4 receptors, suggesting that 263 biosynthesis and transport to the plasma membrane are likely not impaired by these mutations 264 (Sup. Fig 1A) .
266
Lysosomes are the degradative endpoints of most cell surface receptors (54-56). It is possible 267 that the mutant receptors exhibit altered cellular kinetics and are degraded within the lysosome 268 at increased rates. To examine this possibility, we performed a knockdown of cup-5, a gene 269 necessary for lysosome function in C. elegans. We have previously shown that the loss of the 270 retromer subunit, vps-35, leads to the premature degradation of the type I receptor SMA-6 271 within the lysosome which can be reversed by RNAi mediated knockdown of cup-5 (48) . We 272 hypothesized that if the mutant DAF-4 receptors were being degraded in the lysosome, we 273 would observe an accumulation if the lysosome function was blocked. However, there was no 274 change in the receptor levels upon cup-5 RNAi, suggesting that the MFS-like mutations did not 275 lead to an increased rate of degradation within the lysosome (Sup Fig S2) . 
300
We have shown that the presence of MFS-like mutations in the type II receptor leads to the shift 301 in localization from the basolateral surface to the apical surface of the intestine ( Fig 3D) . The 302 increase in body size in the wild-type background and rescue of the small body phenotype of 303 the daf-4(e1364) mutant with the MFS-like mutant receptors, strongly suggests that activity is 304 not diminished with these mutations (Fig 2) . Given the new localization pattern of the mutant 305 DAF-4 receptors and that SMA-6 would be required at the same locations, we asked what the 306 effect of the MFS-like mutations were on the cell biology of the type I receptor, SMA-6. We 307 tested the levels and localization of a functional sma-6::gfp transgene within the intestine in the 308 presence of either wild-type or MFS-like mutant daf-4 receptors (untagged). We observe a 309 significant decrease in overall levels of the type I receptor within the cell when co-expressed with the mutant DAF-4 receptors ( Fig 4A) . The type I receptor is known to recycle through a 311 retromer-mediated mechanism, and a loss of this retromer-receptor interaction leads to 312 degradation of the type I receptor in the lysosome. To identify whether the type I receptor was 313 indeed being degraded in the lysosome, we hypothesized that perturbation of lysosome function 314 would lead to a recovery of GFP-tagged receptors. An RNAi of cup-5 led to the restoration of 315 the GFP signal within the lysosomes indicating that the presence of MFS-mutant type II 316 receptors leads to abnormal degradation of the type I receptor, possibly through disruption of 317 type I-retromer interaction ( Fig 4B) .
319
In the presence of the wild-type DAF-4 receptor, SMA-6::GFP localizes primarily to the 320 basolateral surfaces of the intestinal cells ( Fig 4C) , as has previously been shown (48). In stark 321 contrast, the presence of the mutant DAF-4 receptors leads to a change in localization from the 322 basolateral surface to the apical surface, similar to what we observe for the mutant DAF-4 323 receptors themselves (Fig 3) . The change in localization of SMA-6 in the presence of the mutant 324 DAF-4 receptors suggests that the receptors are dependent on each other for trafficking.
325
Whether this dependency occurs after internalization and separation during recycling or soon 326 after biosynthesis and transport to the plasma membrane needs to be further examined. 
333
prevalence of MFS-like mutations at the LTA motif of type II receptors, which lies within the 334 kinase domain, can potentially lead to defective kinase activity (1, 2, 12) . In vitro structure 335 function assays determining signal output through levels of pSMAD or reporter genes are 336 controversialsome studies showed lowered pSMAD activation while others observed no 337 change in pSMAD levels. In fibroblasts from a TGFβ kinase-deficient mouse, increased 338 signaling was unexpectedly seen in assays of pSmad2 (57). Others have shown that mutant 339 TGFβ receptors maintained kinase ability and that phosphorylated R-Smads were detected (41).
340
In MFS-like patients, it has been demonstrated that specific missense mutations screened 
367
Our in vivo assays found that MFS-like associated mutations in or around the defined LTA motif 368 in the type II receptor affect the trafficking of both TGFβ receptors, although the effect on the 369 type I receptor would be indirect. Wild-type type II receptors tend to be distributed in a web-like 370 manner throughout the cell, but do not have an appreciable apical localization (Fig 3B, D) .
371
However, this apical-to-basolateral distribution ratio is altered in the presence of mutant 372 receptors, with a fraction of the mutant receptors now present at the apical surface. It is 373 interesting to note that not all mutant receptors are apically localized. Since signaling complexes 
401
Although the LTA motif is known to direct trafficking, the molecules that interact with it are 402 currently unknown. We have previously shown that the C. elegans type I receptor requires the 403 retromer for recycling back to the surface while the type II receptor appears to require the small 404 GTPase arf-6, whose loss leads to intra-endosomal accumulation of the type II receptor DAF-4 405 (48). However, loss of the retromer leads to a redistribution from basolateral to a combination of 406 basolateral and apical localization of the type II receptor in MD-1 cells (61), suggesting that 407 receptors that were basolaterally localized have now been resorted to the apical membrane.
408
Consistent with this redistribution, the wild-type C. elegans type II DAF-4 displays some apical 409 localization in a retromer mutant ( Fig 4D) suggesting that the LTA motif of the type II receptor 410 interacts with the retromer.
412
Furthermore, loss of the retromer also reduced recycling by 50-60% in MD-1 cells (61). The type 413 I receptor requires the retromer for recycling, and perhaps this interaction can only take place in 414 the context of the type II receptor LTA-motif-retromer interaction (61). The presence of MFS-like 415 mutations might interfere with this type I-type II-retromer complex and alter separation and 416 recycling dynamics, thereby transiently increasing Smad phosphorylation. The inability of the 417 type I receptor to then interact with the retromer would lead to its sorting into the lysosome for 418 degradation, as we have previously shown. This is consistent with our data showing that the 419 levels of the wild-type type I receptor are significantly reduced in the presence of the MFS-like 420 mutant receptors (Fig. 4A) . Thus, we suggest that the MFS-mutations may disrupt a type II 421 receptor-retromer interaction and lead to a redistribution of signaling complexes to the apical 422 surface. Interestingly, many of these same mutations are also present in many cancer cell lines 423 and tumor specimens ( Fig 1A) . It seems likely that some of these mutations also affect 424 trafficking of the receptors. 
433
All C. elegans strains were derived originally from the wild-type Bristol strain N2, and all strains 434 were grown at 20°C on standard nematode growth media plates seeded with OP50 E. coli.
435
Worm cultures, genetic crosses, and other C. elegans husbandry were performed according to 436 standard protocols (62). RNAi was performed using the feeding method (63). Feeding 437 constructs were from the Ahringer library (64), and empty vector, L4440, was used as a control.
438
For experiments, larval stage L4 animals were used, unless otherwise stated. The daf-4(e1364) 439 mutant strain CB1364 was obtained from the CGC, and maintained at 15°C. For a list of strains, 440 see Supporting Table S1 . 
457
Selected MFS/MFS-like mutations were introduced into the daf-4 receptor using the Q5 Site-458 directed mutagenesis kit from NEB (Catalog # E0554S) and were codon optimized for C. 459 elegans based on the optimal codon usage (C. elegans II. 2nd edition, Table I ).
461
All low-copy stably transformed strains were obtained through micro-particle bombardment. The 462 protocol used was previously described in (65) 
468
For all pvha-6 and pelt-3 constructs, 20 µg of DNA were used for microparticle bombardment.
469
All the transformed worm strains were outcrossed to N2 at least four times. 
